The evaluation of hearing deficits following chemoradiation
Research type
Research Study
Full title
To establish the effects of chemoradiation therapy on hearing, balance and tinnitus in patients treated for head and neck cancer in our local population
IRAS ID
105163
Contact name
Simon Rogers
Contact email
Sponsor organisation
Aintree University Hospital
Research summary
Although hearing loss is a recognised side effect of chemotherapy for H&N cancer there is limited data to establish incidence, severity and success of post treatment intervention. Studies ( Ototoxicity in a randomised phase III trial of intra arterial compared with intravenous cipslatin chemoradiation in patients with locally advanced head and neck cancer – Journal of Clinical otology Vol 25, number 24, August 2007) have shown that there is approximately a 50% incidence of hearing loss and tinnitus following chemotherapy and radiotherapy for head and neck cancer, especially when treated with Cisplatin. The combination of both chemotherapy and radiotherapy increases the risk of hearing loss. We wish to establish the local incidence of hearing loss and tinnitus following treatment with chemoradation therapy in order to be able to provide counselling regarding the possible effects of the treatment and provide effective treatment and rehabilitation once treatment has been completed.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
13/NW/0351
Date of REC Opinion
19 Sep 2013
REC opinion
Further Information Favourable Opinion